Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011;83(7):11-7.

[First results of Ph-negative acute lymphoblastic leukemia therapy of adults according to the protocol of Research Group of Russian Hematological Centers ALL-2009]

[Article in Russian]
E N Parovichnikova, G A Kliasova, V G Isaev, A N Sokolov, A V Kokhno, V V Troitskaia, E V Mavrina, E E Khodunova, E N Ustinova, E O Gribanova, S K Kravchenko, V V Ryzhko, T S Kaporskaia, O Iu Baranova, S N Bondarenkko, A S Nizametdinova, E V Kondakova, T V Ryl'tsova, A N Alufer'eva, O S Samoĭlova, O P Skamorina, L V Gavrilova, A S Pristupa, N A Vopilina, T S Konstantinova, I V Kriuchkova, L V Anchukova, T S Tikunova, K D Kaplanov, V A Lapin, V A Tumakov, M N Kozmina, S A Chernysh, E I Podol'tseva, S M Kulikov, Iu R Davidian, V G Savchenko
  • PMID: 21894746
Clinical Trial

[First results of Ph-negative acute lymphoblastic leukemia therapy of adults according to the protocol of Research Group of Russian Hematological Centers ALL-2009]

[Article in Russian]
E N Parovichnikova et al. Ter Arkh. 2011.

Abstract

Aim: To review results of 2-year experience in execution of the protocol on the treatment of adult acute Ph-negative lymphoblastic leukemia ALL-2009.

Material and methods: Of 111 patients registered in the study from November 2008 to December 2010 the analysis covered 96 patients from 23 hematological centers in 18 towns of the RF.

Results: Treatment according to the Protocol ALL-2009 resulted in achievement of a complete remission in 91.2% patients with low early lethality of 5.5%. Postremission lethality fell to 3.7% versus previous studies (22%). Overall 2-year survival and recurrence-free survival reached 77.6 and 78.4%, respectively. Detection of any chromosomic aberrations significantly affected recurrence-free survival: 74 vs 100% in patients with normal karyotype.

Conclusion: Protocol All-2009 demonstrates high efficacy in moderate toxicity and good reproducibility in any hematologic center.

PubMed Disclaimer

MeSH terms